Chongqing Zhifei Biological Products (300122.SZ) has seven self-developed products on the market, one of which is conditionally listed, including vaccine products for preventing meningitis, pneumonia, and other infectious diseases.

Gelonghui Finance · Jul 5 05:20

Chongqing Zhifei Biological Products (300122.SZ) stated on the investor interaction platform on July 5th that the company has a total of 7 self-developed products on the market, with 1 self-developed product conditionally approved for sale. This includes vaccine products for preventing infectious diseases such as meningitis and pneumonia, as well as pharmaceuticals that provide effective solutions for the diagnosis, prevention, and treatment of tuberculosis infection. The company has 31 research projects, with the quadrivalent influenza vaccine in the declaration stage for market approval. Clinical trials have been completed for lyophilized human rabies vaccine (MRC-5 cell), split influenza virus vaccine, and five other products including 15-valent pneumococcal conjugate vaccine and component pertussis vaccine are in phase III clinical trials.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

智飞生物(300122.SZ)：共有7种自主产品上市在售，1种自主产品附条件上市，包括预防流脑、肺炎等传染病的疫苗产品

Chongqing Zhifei Biological Products (300122.SZ) has seven self-developed products on the market, one of which is conditionally listed, including vaccine products for preventing meningitis, pneumonia, and other infectious diseases.

Risk Disclaimer

Statement